http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Sub-lattice polarization states in anti-ferroelectrics and their relaxation process
M.M. Vopson,X. Tan,E. Namvar,M. Belusky,S.P. Thompson,V. Kuncser,F. Plazaola,I. Unzueta,C.C. Tang 한국물리학회 2019 Current Applied Physics Vol.19 No.4
We report studies of quasi-remanent polarization states in Pb0.99Nb0.02[(Zr0.57Sn0.43)0.94Ti0.06]0.98O3 (PNZST) anti-ferroelectric ceramics and investigation of their relaxation effects using unique in-situ electrically activated time-resolved Synchrotron X-ray powder diffraction (SXPD) and 119Sn Mössbauer Spectroscopy (MS). The SXPD patterns are consistent with a phase transition from quasi-tetragonal perovskite in 0 V relaxed anti-ferroelectric state to rhombohedral distortion in ferroelectric state under saturating applied voltages of±2 kV. The observed quasi-remanent polarization relaxation processes are due to the fact that tetragonal to rhombohedral distortion does not occur at the applied voltage required to access the quasi-remanent polarization states, and the tetragonal symmetry restored after the removal of the applied electric field is preserved. Since these quasi-remanent polarization states were seen as possibly suitable for memory applications, the implications of this study are that anti-ferroelectrics are more feasible for multi-state dynamic random access memories (DRAM), while their application to non-volatile memories requires development of more sophisticated “read-out” protocols, possibly involving dc electrical biasing.
Provencal, J. L.,Montgomery, M. H.,Kanaan, A.,Thompson, S. E.,Dalessio, J.,Shipman, H. L.,Childers, D.,Clemens, J. C.,Rosen, R.,Henrique, P.,Bischoff-Kim, A.,Strickland, W.,Chandler, D.,Walter, B.,Wat IOP Publishing 2012 The Astrophysical journal Vol.751 No.2
<P>We report on an analysis of 308.3 hr of high-speed photometry targeting the pulsating DA white dwarf EC14012-1446. The data were acquired with the Whole Earth Telescope during the 2008 international observing run XCOV26. The Fourier transform of the light curve contains 19 independent frequencies and numerous combination frequencies. The dominant peaks are 1633.907, 1887.404, and 2504.897 mu Hz. Our analysis of the combination amplitudes reveals that the parent frequencies are consistent with modes of spherical degree l = 1. The combination amplitudes also provide m identifications for the largest amplitude parent frequencies. Our seismology analysis, which includes 2004-2007 archival data, confirms these identifications, provides constraints on additional frequencies, and finds an average period spacing of 41 s. Building on this foundation, we present nonlinear fits to high signal-to-noise light curves from the SOAR 4.1 m, McDonald 2.1 m, and KPNO 2 m telescopes. The fits indicate a time-averaged convective response timescale of tau(0) = 99.4 +/- 17 s, a temperature exponent N = 85 +/- 6.2, and an inclination angle of theta(i) = 32 degrees.9 +/- 3 degrees.2. We present our current empirical map of the convective response timescale across the DA instability strip.</P>
Determination of Hund's coupling in 5d oxides using resonant inelastic x-ray scattering
Yuan, Bo,Clancy, J. P.,Cook, A. M.,Thompson, C. M.,Greedan, J.,Cao, G.,Jeon, B. C.,Noh, T. W.,Upton, M. H.,Casa, D.,Gog, T.,Paramekanti, A.,Kim, Young-June American Physical Society 2017 Physical Review B Vol.95 No.23
<P>We report resonant inelastic x-ray scattering (RIXS) measurements on ordered double-perovskite samples containing Re5+ and Ir5+ with 5d(2) and 5d(4) electronic configurations, respectively. In particular, the observedRIXS spectra of Ba2YReO6 and Sr2MIrO6 (M = Y, Gd) show sharp intra-t(2g) transitions, which can be quantitatively understood using a minimal 'atomic' Hamiltonian incorporating spin-orbit coupling. and Hund's coupling J(H). Our analysis yields lambda = 0.38(2) eV with J(H) = 0.26(2) eV for Re5+ and lambda = 0.42(2) eV with J(H) = 0.25(4) eV for Ir5+. Our results provide sharp estimates for Hund's coupling in 5d oxides and suggest that it should be treated on equal footing with spin-orbit interaction in multiorbital 5d transition-metal compounds.</P>
( J Mallolas ),( S Pol ),( A Rivero ),( H Fainboim ),( C Cooper ),( J Slim ),( S Thompson ),( J Wahl ),( W Greaves ),( M Sulkowski ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Addition of boceprevir (BOC) to peginterferon (P) and ribavirin (R) significantly increases SVR among HCVmonoinfected patients for whom SVR rates have been low. The objective of this phase 2 trial was to investigate the efficacy and safety of BOC+P/R in HCV/HIV-coinfected patients. Methods: In this multicenter, double-blind, international trial, patients with untreated hepatitis C genotype 1 infections and HIV RNA <50 copies/mL were randomized 2:1 to receive P (PEG 2b 1.5 ug/kg/wk)/R (600-1400 mg/day, by weight) + BOC 800mg TID or P/R+placebo for 44 weeks, after a 4-week lead-in of P/R. NNRTIs, zidovudine, or didanosine were not permitted. Patients were stratified by: cirrhosis/fibrosis (yes vs. no) and baseline HCV-RNA (<800,000 IU/mL vs ≥800,000 IU/mL). The primary efficacy endpoint was SVR, undetectable plasma HCV-RNA 24 weeks after end of treatment (EOT). Secondary endpoints and planned interim analyses included proportion of subjects with undetectable HCV-RNA at treatment week (TW) 4, 8, 12, 24 and 48/EOT. Results: 100 patients were randomized between 11/2009 and 12/2010; 2 patients in the BOC arm did not receive medication; thus, 34 control and 64 experimental patients were treated. The majority were non-cirrhotic (95%), white (82%), male (69%) with median age ~43 years. Most had high baseline HCV-RNA (88%) and HCV genotype 1a (65%). At TW48/EOT, the rate of undetectable HCV-RNA was 63.9% and 29.4% in the BOC and control arms, respectively (Table). 61% of the BOC group and 32% of the control group completed 48 weeks of treatment; 20% and 9%, respectively, discontinued due to adverse events. HCV treatment failure occurred in 9% of the BOC group and 53% of the control group. BOC patients were more likely than controls to have decreased appetite, pyrexia, dysgeusia, vomiting, asthenia, anemia, and neutropenia. By TW48, 2 patients in the BOC group and 3 in the control group had HIV virologic failure. Conclusion: The addition of BOC to P/R was associated with higher rates of undetectable HCV-RNA at all time points, including TW48/EOT. The safety and tolerability profile was consistent with that observed in HCV-monoinfected patients. PE-136 Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) + PR: The PROVIDE study interim results JP Bronowicki1, M Davis2, S Flamm3, S Gordon4, E Lawitz5, E Yoshida6, J Galati7, V Luketic8, J McCone9, I Jacobson10, P Marcellin11-12, A Muir13, F Poordad14, LD Pedicone15, W Deng15, M Treitel15, J Wahl15, J Vierling16 1University Henri Poincare of Nancy, Vandoeuvre-les-Nancy, France; 2South Florida Center of Gastroenterology, Wellington, FL, USA; 3Northwestern Feinberg School of Medicine, Chicago, IL, USA; 4Henry Ford Hospital, Detroit, MI, USA; 5Alamo Medical Research, San Antonio, TX, USA; 6University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada; 7Liver Specialists of Texas, Houston, TX, USA; 8Virginia Commonwealth University School of Medicine, Richmond, VA, USA; 9Mt. Vernon Endoscopy Center, Alexandria, VA, USA; 10Weill Cornell Medical College, New
Chia, Elbert E. M.,Talbayev, D.,Zhu, Jian-Xin,Yuan, H. Q.,Park, T.,Thompson, J. D.,Panagopoulos, C.,Chen, G. F.,Luo, J. L.,Wang, N. L.,Taylor, A. J. American Physical Society 2010 Physical Review Letters Vol.104 No.2
<P>We report measurements of quasiparticle relaxation dynamics in the high-temperature superconductor (Ba,K)Fe2As2 in optimally doped, underdoped, and undoped regimes. In the underdoped sample, spin-density wave (SDW) order forms at approximately 85 K, followed by superconductivity at approximately 28 K. We find the emergence of a normal-state order that suppresses SDW at a temperature T{*} approximately 60 K and argue that this normal-state order is a precursor to superconductivity.</P>
Electrical spin injection into moderately doped silicon enabled by tailored interfaces
Jansen, R.,Min, B. C.,Dash, S. P.,Sharma, S.,Kioseoglou, G.,Hanbicki, A. T.,van ’t Erve, O. M. J.,Thompson, P. E.,Jonker, B. T. American Physical Society 2010 Physical review. B, Condensed matter and materials Vol.82 No.24
( J Mallolas ),( S Pol ),( A Rivero ),( H Fainboim ),( C Cooper ),( J Slim ),( S Thompson ),( J Wahl ),( W Greaves ),( M Sulkowski ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Addition of boceprevir (BOC) to peginterferon (P) and ribavirin (R) significantly increases SVR among HCV- monoinfected patients for whom SVR rates have been low. The objective of this phase 2 trial was to investigate the efficacy and safety of BOC+P/R in HCV/HIV-coinfected patients. Methods: In this multicenter, double-blind, international trial, patients with untreated hepatitis C genotype 1 infections and HIV RNA <50 copies/mL were randomized 2:1 to receive P (PEG 2b 1.5 ug/kg/wk)/R (600-1400 mg/day, by weight) + BOC 800mg TID or P/R+placebo for 44 weeks, after a 4-week lead-in of P/R. NNRTIs, zidovudine, or didanosine were not permitted. Patients were stratified by: cirrhosis/fibrosis (yes vs. no) and baseline HCV-RNA (<800,000 IU/mL vs ≥800,000 IU/mL). The primary efficacy endpoint was SVR, undetectable plasma HCV-RNA 24 weeks after end of treatment (EOT). Secondary endpoints and planned interim analyses included proportion of subjects with undetectable HCV-RNA at treatment week (TW) 4, 8, 12, 24 and 48/EOT. Results: 100 patients were randomized between 11/2009 and 12/2010; 2 patients in the BOC arm did not receive medication; thus, 34 control and 64 experimental patients were treated. The majority were non-cirrhotic (95%), white (82%), male (69%) with median age ~43 years. Most had high baseline HCV-RNA (88%) and HCV genotype 1a (65%). At TW48/EOT, the rate of undetectable HCV-RNA was 63.9% and 29.4% in the BOC and control arms, respectively (Table). 61% of the BOC group and 32% of the control group completed 48 weeks of treatment; 20% and 9%, respectively, discontinued due to adverse events. HCV treatment failure occurred in 9% of the BOC group and 53% of the control group. BOC patients were more likely than controls to have decreased appetite, pyrexia, dysgeusia, vomiting, asthenia, anemia, and neutropenia. By TW48, 2 patients in the BOC group and 3 in the control group had HIV virologic failure. Conclusion: The addition of BOC to P/R was associated with higher rates of undetectable HCV-RNA at all time points, including TW48/EOT. The safety and tolerability profile was consistent with that observed in HCV-monoinfected patients.